DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin™ Peanut in Toddlers Viaskin Peanut showed...

Related Keywords

United States ,France ,Colorado ,Montrouge ,France General ,American ,Katie Matthews ,Matthew Greenhawt ,Eleanor Garrow ,Angela Marcucci ,Matthewc Greenhawt ,Anaphylaxis Connection Team ,Company Adss ,American College Of Allergy ,Exchange Commission ,Year Results ,Ongoing Phase ,Label Extension ,American College ,Nasdaq Stock Market ,Open Label Extension ,Viaskin Peanut ,Daniel Tass ,Chief Executive Officer ,Annual Scientific Meeting ,New England Journal ,Hospital Colorado ,Breaking Abstract ,Peanut Allergic Toddlers ,Anschutz Medical Campus ,Late Breaking Oral Abstracts ,Poster Area ,Eleanor Garrow Holding ,Food Allergy ,Anaphylaxis Connection ,Conference Call ,North American ,Basking Ridge ,Euronext Paris ,Nasdaq Global Select Market ,Des March ,Markets ,